What is Small Molecule Targeted Drugs?

Introduction

The field of modern medicine has been transformed by the development of small molecule targeted drugs. Targeted drugs work by interacting with specific molecular targets within disease pathways to provide treatment solutions that outperform conventional therapies both in accuracy and effectiveness. This article explores the defining properties and operating principles of small molecule targeted drugs while contrasting them with macromolecular drugs and examining common examples together with current obstacles and prospective advancements.

Mechanisms of Achieving Targeting in Small Molecule Drugs

Classification Based on Targeting Levels

• Tissue/Organ - Level Targeting

Tumor tissues' enhanced permeability and retention (EPR) effect enables drugs to accumulate at tumor sites without active transport. Sorafenib obstructs tumor growth by blocking the vascular endothelial growth factor receptor which controls angiogenesis.

• Cell - Level Targeting

• Signal Pathway Regulation: Therapeutic interventions on membrane and intracellular signaling molecules involve using inhibitors like EGFR and ALK kinase blockers.
• Protein Metabolism Regulation: The proteasome inhibitor Bortezomib causes tumor cell death by interrupting the abnormal protein degradation process.

• Sub - cell - Level Targeting

• Nuclear Targets: Chidamide functions as an HDAC inhibitor which suppresses tumor gene expression through epigenetic regulation mechanisms.
• Mitochondrial Targeting: Small molecules cause cell apoptosis through disruption of mitochondrial function.

Classification Based on Targeting Strategies

• Passive Targeting

It relies on physiological structural differences (such as the leakiness of tumor blood vessels) to achieve drug enrichment without active modification.

• Active Targeting

• Ligand - Receptor Binding: By coupling antibody fragments or polypeptides (such as nucleic acid aptamers), the specific binding to the target is enhanced. Molecular Glues, for example, induce the binding of target proteins to E3 ubiquitin ligases, promoting protein degradation.
• Allosteric Regulation: Asciminib selectively inhibits kinase activity by binding to the allosteric site of BCR - ABL.

Figure 1. The principles of targeted cancer therapy. (Sources: Gatzka MV. 2018)

• Physical Targeting

External stimuli such as light, heat, or magnetic fields are used to control drug release. For example, light - responsive nanocarriers can deliver small molecule drugs to tumor sites.

Typical Cases of Targeted Small Molecule Drugs

Imatinib

The first tyrosine kinase inhibitor targeting the BCR - ABL fusion protein, which has significantly increased the 5 - year survival rate of chronic myeloid leukemia patients to 90%.

Osimertinib

A third - generation EGFR inhibitor that selectively inhibits the T790M resistance mutation and can cross the blood - brain barrier to treat lung cancer brain metastases.

Venetoclax

A BCL-2 inhibitor that treats chronic lymphocytic leukemia by targeting the mitochondrial apoptosis pathway.

PROTACs (Protein Degradation Targeting Chimeras)

Such as ARV - 471 (targeting the estrogen receptor) and ARV - 110 (targeting the androgen receptor), which degrade oncogenic proteins through the ubiquitin - proteasome system.

Conclusion

The targeting of small molecule drugs is achieved through structural design, target selection, and delivery strategies to precisely regulate disease - related molecules. Although drug resistance and off-target effects present challenges for these compounds their chemical tunability alongside intracellular action capability and oral delivery convenience ensures they remain vital in treating oncology and immune diseases. Small molecule drug targeting will reach new levels of progress through integration with emerging technologies like PROTACs and RNA targeting which will advance personalized medicine.

Anti-Small Molecule Antibodies

Small Molecule Haptens